Composite biomaterials based on sol-gel mesoporous silicate glasses: a review by Baino, Francesco et al.
04 August 2020
POLITECNICO DI TORINO
Repository ISTITUZIONALE
Composite biomaterials based on sol-gel mesoporous silicate glasses: a review / Baino, Francesco; Fiorilli, SONIA
LUCIA; VITALE BROVARONE, Chiara. - In: BIOENGINEERING. - ISSN 2306-5354. - ELETTRONICO. - (2017), pp. 1-
18.
Original
Composite biomaterials based on sol-gel mesoporous silicate glasses: a review
Publisher:
Published
DOI:10.3390/bioengineering4010015
Terms of use:
openAccess
Publisher copyright
(Article begins on next page)
This article is made available under terms and conditions as specified in the  corresponding bibliographic description in
the repository
Availability:
This version is available at: 11583/2666001 since: 2017-03-01T12:42:48Z
MDPI
 Bioengineering 2017, 3, 15; doi:10.3390/bioengineering4010015  www.mdpi.com/journal/bioengineering 
Review 
Composite Biomaterials Based on Sol-Gel 
Mesoporous Silicate Glasses: A Review 
Francesco Baino *, Sonia Fiorilli and Chiara Vitale-Brovarone 
Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino 
10129, Italy; sonia.fiorilli@polito.it (S.F.); chiara.vitale@polito.it (C.V.-B.) 
* Correspondence: francesco.baino@polito.it; Tel.: +39-011-090-4668 
Academic Editor: Jacqueline J. Alblas 
Received: 20 December 2016; Accepted: 17 February 2017; Published: 23 February 2017 
Abstract: Bioactive glasses are able to bond to bone and stimulate the growth of new tissue while 
dissolving over time, which makes them ideal materials for regenerative medicine. The advent of 
mesoporous glasses, which are typically synthesized via sol-gel routes, allowed researchers to 
develop a broad and versatile class of novel biomaterials that combine superior bone regenerative 
potential (compared to traditional melt-derived glasses) with the ability of incorporating drugs and 
various biomolecules for targeted therapy in situ. Mesoporous glass particles can be directly 
embedded as a bioactive phase within a non-porous (e.g., microspheres), porous (3D scaffolds) or 
injectable matrix, or be processed to manufacture a surface coating on inorganic or organic 
(macro)porous substrates, thereby obtaining hierarchical structures with multiscale porosity. This 
review provides a picture of composite systems and coatings based on mesoporous glasses and 
highlights the challenges for the future, including the great potential of inorganic–organic hybrid 
sol-gel biomaterials. 
Keywords: bioactive glass; mesoporous; composite; scaffold; tissue engineering  
 
1. Introduction 
Bioactive glasses are amorphous materials that can bond to hard and soft tissues and stimulate 
the regeneration of healthy bone while dissolving over time, which makes them highly attractive 
candidates for healthcare and a 21st century biomedicine [1]. The first bioactive glass, belonging to 
the 45SiO2–24.5Na2O–24.5CaO–6P2O5 (wt %) system (45S5 Bioglass®), was developed by Larry L. 
Hench at the University of Florida (USA) [2] and has been clinically used in a number of orthopedic 
and dental applications since the 1980s [3].  
In the context of bone repair, “inorganic bioactivity” denotes the formation of a nano-crystalline 
apatite layer mimicking the mineral phase of bone on the implant surface, which is a precondition so 
that a tight bond to calcified tissues can occur [4]. While SiO2 should be less than 60 mol % in  
melt-derived glasses to allow the material to bond to bone as a consequence of the bioactive process 
[5], surface apatite formation was interestingly observed in glasses that contain up to 90 mol % of 
SiO2 if they are synthesized via a sol-gel process that creates an inherent mesoporosity (2–50 nm) in the 
material [6]. Hence, sol-gel glass particles are characterized by a high surface area available for the release 
of soluble ionic species (tens of m2/g compared to less than 1 m2/g of melt-derived glass products of equal 
size) and, thereby, bioactive reactions are significantly emphasized and accelerated [7].  
Incorporation of supramolecular chemistry into the sol-gel process (Figure 1a) led to the advent 
of ordered silicate mesoporous materials [8], which have been proposed over the last 15 years as 
versatile platforms for the controlled release of drugs and growth factors that can be entrapped inside 
an ordered array of mesopores [9–11]. Classification of pore sizes according to International Union 
of Pure and Applied Chemistry （IUPAC）definitions [12] is schematically depicted in Figure 1b. 
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It is important to note that the so-called mesoporous bioactive glasses (MBGs) [13], which are 
typically synthesized by using a surfactant as mesopore template, are unique compared to 
“conventional” sol-gel bioactive glasses. In fact, although both types of glasses are produced by a wet 
method (sol-gel) and characterized by nanopores at the mesoscale (2–50 nm), the mechanism for the 
generation of the mesoporous texture is different: conventional sol-gel glasses possess mesopores 
which arise from the random distribution of CaO within the network of SiO2 [14]; on the contrary, 
the self-assembly of micelles in MBGs gives rise to uniform mesopores as well as ordered 
mesostructures with higher specific surface area (hundreds of m2/g). Under N2 adsorption–
desorption analysis, conventional sol-gel glasses typically show H2-type hysteresis loops associated 
with inkbottle-like pores, while MBGs exhibit H1-type hysteresis loops typical of 1D spatially-ordered 
channels [13].  
SiO2-based mesoporous materials, which are usually produced in the form of micro- or nano-
sized particles, can be added to a polymeric or inorganic matrix by direct mixing or surface coating 
strategies in order to produce composites with suitable characteristics for medical applications, such 
as hierarchical 3D porous scaffolds or injectable cements. This review provides a state-of-the-art 
picture about the above-mentioned composites as well as a prospect for future research, highlighting 
the potential of hybrid systems in which the organic and inorganic phases are intimately linked at 
the nanoscale. In fact, hybrids allow many limitations of “traditional” nanocomposites to be 
overcome, keeping the best of the two components to produce a high-performance single-phase 
material with superior properties.  
 
Figure 1. Basic concepts related to mesoporous materials: (a) molecular self-assembling of surfactant 
micelles to originate mesopores and (b) pore size scales according to IUPAC terminology. Images 
adapted from Owens et al. [15] © Elsevier. 
2. Hierarchical Glass-Based Composites Produced by “Mixing Strategies” 
Incorporation of an inorganic phase into a polymeric matrix is a valuable strategy to improve 
the performance of the base material and impart extra-functionalities, primarily high strength and 
bioactivity. An overview of these applications is reported in Table 1.  
Collagen hydrogels, having similar composition to the bone extracellular matrix, are excellent 
platforms for the anchorage and spreading of cells, as well as for their subsequent proliferation and 
differentiation into target tissue lineages. However, one of the major drawbacks of collagen is its high 
rate of hydrolytic and enzymatic biodegradability, which limits the use of collagen hydrogels as 
biological constructs [16]. El-Fiqi et al. [17] showed that the addition of MBG nanoparticles (50–100 
nm) as a second phase can be a valuable strategy to improve the performance of collagen hydrogels 
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in terms of physico-chemical and mechanical properties (Figure 2) as well as biological behavior upon 
in vitro tests with mesenchymal stem cells. 
Mesoporous silicate glass particles have been added as a bioactive phase to otherwise nearly-
inert polymeric matrices in a number of studies. El-Kady et al. [18] incorporated sol-gel glass (60SiO2-
36CaO-4P2O5 wt %) nanoparticles (size below 100 nm) into poly(L-lactic acid) (PLLA) scaffolds, 
produced by the solid–liquid phase separation method combined with solvent extraction, and 
observed the formation of a surface apatite layer upon in vitro tests; furthermore, the degradation 
rate of these composite scaffolds could be tailored according to the amount of silicate phase. Li et al. 
[19] prepared MBG/poly(lactic-co-glycolic acid) (PLGA) microspheres for obtaining a more sustained 
release of gentamicin over time. The same research group also experimented a solvent 
casting/particulate leaching route to fabricate MBG/poly(caprolactone) (PCL) composite scaffolds 
with improved drug release ability and high bioactivity in vitro [20]. For analogous purposes, 
MBG/alginate microspheres [21] and MBG/PLGA films [22] were prepared in other studies. 
Table 1. Hierarchical composites containing a mesoporous glass phase. 
Mesoporous 
Phase 
Matrix Processing Effect References 
MBG Collagen Mixing 
Improved bioactivity in vitro 
and mechanical properties 
[17] 
Sol-gel glass PLLA 
Solid–liquid phase separation 
+ solvent extraction 
Improved bioactivity in vitro [18] 
MBG PLGA Mixing 
Improved bioactivity in vitro, 
drug release 
[19,22] 
MBG Polyamide 
Solvent casting/particulate 
leaching 
Improved bioactivity in vitro 
and bone regeneration in vivo 
[23] 
MBG PCL 
Solvent casting/particulate 
leaching 
Improved bioactivity in vitro, 
drug release 
[20] 
Robocasting + salt leaching 
Improved bioactivity in vitro 
and mechanical properties, 
pliability 
[24] 
MBG Alginate 
Mixing 
Improved bioactivity in vitro, 
drug release 
[21] 
3D plotting 
Improved bioactivity in vitro, 
drug release 
[25] 
MBG Silk fibroin Freeze-drying 
Improved bioactivity in vitro 
and mechanical properties 
[26,27] 
MBG 
Calcium 
phosphate 
Mixing + freeze-drying 
Adequate mechanical 
properties and bone 
regeneration in vivo 
[28] 
MBG Chitosan Freeze-drying 
Hemostasis to promote wound 
healing 
[29] 
MBG: mesoporous bioactive glasses; PLLA: poly(L-lactic acid); PLGA: poly(lactic-co-glycolic acid); 
PCL: poly(caprolactone). 
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Figure 2. MBG/collagen nanocomposite obtained by freeze-frying: (a) schematic illustration of the 
material structure and function (ion release from MBG nanoparticles is expected to promote 
bioactivity and cellular mineralization, and the surface functionalization of MBG with amino groups 
facilitates chemical links with amino-acid sequences of collagen molecules, which enables the 
physico-chemical stability of the hydrogels); (b) scanning electron microscopy (SEM) micrograph of 
the hydrogel structure; and (c) detail showing the collagen fibrils integrated with MBG nanoparticles. 
Images adapted from El-Fiqi et al. [17] © Elsevier. 
Su et al. used a solvent casting/particulate leaching strategy to produce MBG/polyamide 
scaffolds that exhibited excellent biocompatibility as well as superior bone regeneration potential in 
vivo (rabbit’s thighbone defects) compared to the polymeric material alone used as a reference [23]. 
Yun et al. [24] combined salt leaching with robocasting to obtain MBG/PCL composite scaffolds 
exhibiting three-level multiscale porosity, i.e., giant macropores around 200 μm, mid-size 
macropores within 2 to 9 μm, and mesopores of 5 nm. The scaffolds were fabricated by directly 
extruding the gel paste onto a chilled substrate using a robotic deposition device. A gantry 
robocasting apparatus was used with three axes of motion control (x, y and z-axis) and a syringe was 
affixed as a reservoir on the z-axis motion stage. The gel paste housed in the syringe was deposited 
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through a cylindrical nozzle (500 μm); a linear actuator served to depress the plunger of the syringe 
at a fixed speed so that the volumetric flow rate could be precisely controlled. The shapes and sizes 
of the scaffold as well as the arrangement of the macropores could be controlled by a computer system 
(Figure 3). These highly interesting constructs possessed adequate compressive strength (2–4 MPa) for 
bone repair, good in vitro bioactivity and a versatile sponge-like plastic nature with easy pliability, which 
suggested possible use as injectable scaffolds for minimally invasive surgery (Figure 3). 
 
Figure 3. Compressibility of MBG/PCL composite scaffolds produced by robocasting (images adapted 
from Yun et al. [24] © Elsevier). 
MBG/alginate pastes were also processed by 3D plotting [25] to fabricate hierarchical scaffolds 
provided with good biocompatibility, drug release properties and mineralization ability in vitro upon 
soaking in an inorganic simulated body fluid (SBF) that mimicked the composition of human plasma 
[4]. However, the mechanical properties were not completely satisfactory (1–1.5 MPa for as-such 
scaffolds and 0.5–0.8 MPa after immersion for 28 days in SBF) [25]. 
Silk fibroin and spray-dried MBG particles were also used to fabricate porous composites by 
freeze-drying: compared to the pure silk constructs, the hierarchical macro-mesoporous scaffolds 
exhibited an improved mechanical strength (up to 1 MPa) and a fast apatite-forming ability in vitro 
(hydroxyapatite agglomerates visible after 1 day in SBF) [26]. Similar results were obtained 
incorporating MBG particles obtained by a “conventional” wet synthesis into macroporous silk 
scaffolds [27]. 
Extending the application from organic/inorganic composites to biphasic ceramics, Li et al. [28] 
used a centrifugal embedding approach to fabricate a composite scaffold by combining MBG particles 
and calcium phosphate cement; bone morphogenetic proteins-2 (BMP-2) were also incorporated into 
this construct through a freeze-drying process. The obtained scaffolds exhibited a hierarchical pore 
structure (giant open pores of about 200 μm, macropores within 2 to 10 μm and mesopores of 5 nm), 
a nearly-adequate strength for bone repair (up to 1.4 MPa in compression), and supported the 
sustained release of BMP-2 over 7 days with excellent osteogenesis in a rabbit model. 
As for the applications in soft tissue engineering, freeze-dried MBG/chitosan porous composite 
films were recently proposed as hemostatic membranes for wound healing [29]. Ultrathin MBG fibers 
(diameter of a few hundreds of nanometers) were prepared by Hong et al. [30] via electrospinning 
for possible use in skin tissue engineering; the same research group also demonstrated that the fibers 
could be prepared with a hollow core by a careful optimization of the processing parameters [31]. To 
the best of our knowledge, no other studies dealing with the fabrication of fibrous MBGs have been 
reported in the literature, perhaps due to the high cost associated to the electrospinning equipment 
needed for the mesoporous fiber production. Incorporation of such a bioactive phase in a polymeric 
matrix to obtain a MBG fiber-containing composite would deserve investigation in a future work.  
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3. Macroporous Scaffolds Provided with a Mesoporous Glass Coating  
Deposition of a sol-gel glass coating on the struts of both inorganic and organic scaffolds was a 
key to impart extra-functionalities to the base 3D (macro)porous material—primarily bioactivity and 
drug delivery capability. An overview of these applications is reported in Table 2.  
Perhaps the first relevant study was reported by Miao [32] who dip-coated highly-porous (80 
vol %) Al2O3 foams with a thin layer of “conventional” 58S sol-gel glass (60SiO2-36CaO-4P2O5 mol %) 
in order to impart apatite-forming ability to the otherwise nearly-inert ceramic skeleton. The same 
deposition strategy was carried out by Liu et al. [33] who applied a layer of 58S glass on the struts of 
80Al2O3–20ZrO2 (vol %) ceramic scaffolds. The obtained hierarchical porous composite exhibited 
adequate porosity (60–66 vol % with large and interconnected macropores of 1–2 mm) and 
compressive strength (5–8 MPa) for bone substitution, along with good bioactive properties in vitro 
as revealed by the formation of a surface apatite layer after 1 day in SBF. 
The presence of a sol-gel glass coating may also contribute to mechanically reinforce the 
structure of the base scaffold, as demonstrated by a few studies. A significant improvement of the 
mechanical properties of calcium phosphate scaffolds was achieved by applying a 58S/PCL 
composite coating (dipping procedure); specifically, it was observed that the compressive strength 
(0.2–1.5 vs. 0.1 MPa) and elastic modulus (20–50 MPa vs. 15 MPa) were strongly dependent on the 
amount of 58S glass (1–90 wt %) introduced into the coating [34]. In another study, Esfahani et al. [35] 
coated highly-porous (83 vol %) scaffolds of bovine-derived hydroxyapatite with a thin layer of 58S 
glass by a prolonged dipping procedure to increase the compressive strength of the material from 
0.22 to 1.49 MPa. 
Besides the “conventional” sol-gel glasses, mesoporous materials (both pure amorphous SiO2 
and MBGs), too, were deposited as smart coatings on the struts of a variety of 3D scaffolds with the 
specific purpose of obtaining multifunctional systems that could combine bioactivity, mechanical 
support to the host and regenerated bone tissue, and drug release properties. The first prototype of 
such a construct comprised a bioactive glass–ceramic macroporous foam coated with a micrometric 
layer of SBA-15 spheres (mesopores within 5 to 8 nm) [36]. This early study was then extended to 
MCM-41 (Figure 4a,b) that, having a narrow size of mesopores (2–3 nm), should have allowed a finer 
control of the release kinetics of ibuprofen (drug molecule size about 1 nm) [37–39]. In both cases, the 
pure SiO2 mesoporous glass coating played a key role, on the one hand in enhancing the drug 
adsorption ability of the porous construct and, on the other hand, in allowing a long-term release of 
the therapeutic molecules. A similar approach was also proposed by Boccardi et al. [40] who 
synthesized submicronic MCM-41 spheres directly on 45S5 Bioglass®-derived glass–ceramic scaffolds 
through a modified Stöber method. 
From the viewpoint of regenerative medicine, the major limitation of pure SiO2 mesoporous 
materials is their moderate reactivity in contact with biological fluids: in fact, although MCM-41 and 
SBA-15 were shown able to form a surface apatite layer upon prolonged immersion in SBF [41,42], 
the reaction kinetics are too slow to consider them as effective materials for bone repair. With these 
concerns in mind, researchers introduced other oxides (primarily CaO and P2O5) into the silica 
network to obtain MBGs with exceptional apatite forming ability [43]. These materials have been 
often proposed in the form of fine particulate or somehow processed (e.g., sponge replication, 3D 
printing) to obtain 3D macro-mesoporous scaffolds [44], and more rarely have been applied as 
coatings on preexisting porous substrates. Recently, MBG particles were deposited on CaSiO3-
containing macroporous foams by the electrophoretic mechanism in order to combine the excellent 
bioactivity of the mesoporous phase (Figure 4c,d) with the high mechanical strength (above 15 MPa 
under compressive loads) of the glass–ceramic skeleton [45]. A similar approach was also employed 
to deposited spray-dried Sr-containing MBG spheres on glass–ceramic scaffolds to improve bone 
regeneration as strontium is known to exhibit osteogenic and bone antiresorptive properties [46].  
With the same purpose in mind, Zhang et al. [47] used a spin coating method to deposit a thin 
layer (about 100 nm) of nano-sized MBG on the struts of a 3D-printed β-tricalcium phosphate (TCP) 
scaffold to improve its bone regenerative potential, which was actually confirmed by in vivo tests in 
rabbits. 
Bioengineering 2017, 3, 15  7 of 18 
Shi et al. [48] fabricated MBG/PLGA-coated CaSiO3 scaffolds by dipping the macroporous 
template in a polymer solution with different amounts of suspended nano-sized MBG particles. 
Compared to PLGA/CaSiO3 scaffolds, the compressive strength significantly increased due to the 
presence of MBG particles embedded in the surface coating (1.5–2 vs. 0.4 MPa). Furthermore, the 
bioactive surface layer enhanced the in vitro mineralization ability, the proliferation and early cell 
differentiation of osteoblasts, and allowed a controlled release of ibuprofen to be achieved. 
In a very interesting study, Ye et al. [49] coated hydroxyapatite porous orbital implants with a 
Cu-doped MBG coating to combine the bactericidal effects of Cu2+ ions released as the coating 
degrades and ofloxacin, an antibiotic which was encapsulated in the mesopores of the glass (Figure 
4e,f). This composite device exhibited antibacterial activity against both gram-positive (Staphylococcus 
aureus) and gram-negative bacteria (Escherichia coli), thereby opening new perspectives for the 
prevention and treatment of implant-related ocular infections. 
In the field of bioresorbable scaffolds based on phosphate glasses, Novajra et al. [50] recently 
developed fibrous scaffolds obtained by thermally bonding non-porous phosphate glass fibers 
enriched with MBG particles. The developed scaffolds showed a compressive strength of 3.5 MPa, a 
very high bioactivity and drug release ability due to the presence of mesoporous particles on the fiber 
surface. 
While abundant literature can be found about the development of glass/polymer porous 
composites, especially when comprising the well-known (non-porous) 45S5 Bioglass® [51,52], there 
is a paucity of studies dealing with polymeric scaffolds coated by mesoporous glass. Zhu et al. [53] 
applied a layer of MBG particles on the surface of macroporous poly(L-lactic acid) (PLLA) scaffolds 
by dip-coating in order to impart bioactive properties and drug uptake/release capability to the 
polymeric skeleton. For the same purpose, MBG particles were also deposited on the struts of poly(3-
hydroxybutyrate-co-3-hydroxyhexanoate) scaffolds obtained by 3D printing [54]. 
An interesting application, which can be actually considered an optimization of the sponge 
replica method to produce cellular glasses, was recently reported by Cabanas-Polo et al. [55] who 
exploited the electrophoretic mechanism in the processing of 60.8SiO2-30.9CaO-5.8Na2O-2.4P2O5 (mol 
%) sol-gel glass foams. In this electrophoresis-guided approach, the sol precursor molecules 
(positively charged) travelled from the surroundings of the counter-electrode to a Ni wire fixed to a 
polyurethane foam (cathode), thereby allowing a homogeneous impregnation of the porous substrate 
to be obtained. At the end of the process, the sol-coated polymeric template was left to dry and 
thermally-treated to obtain a sintered glass replica of the foam. 
Occasionally, sol-gel glass has also been used to produce coatings on the surface of metallic 
porous substrates. From a general viewpoint, fabrication of bioactive glass monolithic coatings on 
metal implants is challenging due to a series of problems associated with high-temperature sintering 
required for the consolidation of the bioactive layer, including the risk of oxidation of the metal 
surface and the mismatch between the thermal expansion coefficients of metal and glass. A solution 
to these issues comes from the development of polymer/glass coatings that can adhere to the metallic 
substrate at low temperatures. An interesting study was reported by Yazdimamaghani et al. [56] who 
applied a PCL/gelatin coating reinforced with 64SiO2-31CaO-5P2O5 (mol %) sol-gel glass particles on 
the surface of magnesium scaffolds by means of a freeze-drying process. The presence of the bioactive 
coating induced the growth of a surface apatite layer on the scaffold struts and, perhaps most 
importantly, played a protective role on the metal lying underneath. In fact, it was observed that pure 
magnesium scaffolds were fully degraded after 3 days in SBF, whereas about 87 wt % of 
PCL/gelatin/glass-coated samples remained after immersion for 14 days in the testing solution. 
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Table 2. Scaffolds provided with a mesoporous coating. 
Coating Base scaffold Processing Effect References
58S Al2O3 Dip-coating Improved bioactivity in vitro [32] 
58S Al2O3/ZrO2 Dip-coating Improved bioactivity in vitro [33] 
58S/PCL Calcium phosphate Dipping Improved mechanical properties [34] 
58S 
Bovine 
hydroxyapatite 
Dipping Improved mechanical properties [35] 
SBA-15 Glass–ceramic Dipping Drug release [36] 
MCM-41 Glass–ceramic Dipping Drug release [37–39] 
MBG Glass–ceramic 
Electrophoretic 
deposition 
Improved bioactivity in vitro [45,46] 
MBG β-TCP Spin coating Improved bioactivity in vitro [47] 
MBG/PLGA CaSiO3 Dipping 
Improved bioactivity in vitro and 
mechanical properties, drug 
release 
[48] 
Cu-doped MBG Hydroxyapatite Dipping 
Drug release and antibacterial 
effect due to the release of Cu2+ 
ions 
[49] 
MBG 
Phosphate glass 
fibers 
Thermal bonding 
Improved bioactivity in vitro, drug 
release 
[50] 
MBG PLLA Dip-coating 
Improved bioactivity in vitro, drug 
release 
[53] 
PCL/gelatin/sol-gel 
glass 
Magnesium Freeze-drying 
Improved bioactivity in vitro, 
reduction of magnesium 
dissolution 
[56] 
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Figure 4. Ceramic scaffolds provided with a mesoporous coating (SEM micrographs are reported): (a) 
MCM-41 spheres deposited on a bioactive glass–ceramic foam; and (b) detail of the pure silica 
mesoporous particles anchored on the scaffold struts (images adapted from Vitale-Brovarone et al. 
[38] © Springer); (c) CaSiO3-based scaffold coated with a MBG coating deposited by electrophoretic 
deposition to improve bioactivity, as demonstrated by the surface apatite agglomerates formed after 
2 days in SBF (simulated body fluid) (d) (images adapted from Fiorilli et al. [45] © Springer); (e,f) Cu-
doped MBG layer applied on a hydroxyapatite orbital implant to impart antibacterial properties 
(images adapted from Ye et al. [49] © Springer).. 
4. Sol-Gel Glass Coatings on Prosthetic Devices  
Bioactive glass coatings have been usually produced by enameling on the surface of metallic and 
ceramic prostheses [57]; however, this approach is not very adequate if sol-gel glasses have to be 
processed as the high-temperature firing step required for the sintering and consolidation of the 
coating could involve the elimination of the nanoporosity. Perhaps this was the reason why—along 
with some general concerns about the long-term adhesion of bioactive glass coatings to metallic 
prostheses [58]—the research involving sol-gel glasses was primarily addressed to other applications 
(e.g., 3D scaffolds), except for a few studies. Schrooten and Helsen [59] combined an experimental 
approach with SEM analysis to evaluate the adhesion strength of plasma-sprayed bioactive 52SiO2-
30.5CaO-9.8Na2O-6.2P2O5-1.5CaF2 (mol %) sol-gel glass coatings on titanium dental implants. The 
coating was able to withstand a maximum tensile stress of 47 MPa; adhesion tests performed after 2 
months in SBF revealed that the adhesion strength of the coating decreased by about 10% but the 
interface between the glass and titanium implant remained fully intact at all times. However, no 
evidence of the persistence of the mesoporous structure in the glass after firing was reported.  
Esfahani et al. [60] dip-coated nickel-titanium (Nitinol®) nails with a composite layer made of 
nano-sized 58S glass and titanium oxide (TiO2) produced via a sol-gel route. The 58S particles (50–60 
nm) dispersed in the TiO2 matrix enhanced the hardness of the coating and a direct pull-out test 
recorded a coating–substrate bonding strength larger than 16 MPa. Furthermore, in vitro bioactivity 
studies showed the formation and growth of hydroxyapatite agglomerates on the surface of the 
58S/TiO2-coated Nitinol® alloy upon soaking in SBF, while the as-such implant had a bioinert 
behavior. 
5. Injectable Cements Containing Mesoporous Silicate Materials  
Implant fixation to the patient’s host bone is vital to ensure the long-term success of an 
orthopedic joint prosthesis. At present, the most popular strategy involves the use of acrylic bone 
cement that acts as a grouting material at the bone–implant interface [61]. A variety of materials, such 
as carbon nanotubes [62] and TiO2 fibers [63], have been incorporated within the powder or monomer 
component prior to mixing in the attempt to enhance the static and dynamic mechanical properties 
of the final bone cement. Despite promising in vitro results [64], however, issues concerning the 
interfacial adhesion between acrylic matric and reinforcing phase, high stiffness and poor handling 
characteristics have generally prevented these composite cements from transitioning from the bench 
to clinical applications [65].  
In the last few years, mesoporous materials have also been proposed as a second phase to add 
to bone cement for overcoming the above-mentioned challenges. Slane et al. [66] incorporated 
different amounts of mesoporous silica nanoparticles (MSNs) (0.5, 2 and 5 wt %) to a commercially-
available acrylic cement and evaluated the impact on the static mechanical properties, fatigue life and 
hydration properties. It was reported that the flexural and compressive moduli, the compressive 
strength and the hydration degree increased with increasing concentration of MSNs, whereas the 
flexural strength and fracture toughness significantly decreased. The obtained results suggested that 
the interfacial adhesion strength between MSNs and acrylic matrix was poor, thereby leading to a 
decrease in the flexural and fatigue properties; problems of mixing between the two phases were also 
reported. The dispersion of the particles within the polymer was improved by the surface 
functionalization of the MSNs with amino groups (Figure 5a) [67]. 
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In another study, Li et al. [68] prepared composite cement pellets by mixing calcium sulfate α-
hemihydrate and MSNs, which were surface-functionalized with aminopropyltriethoxysilane (APS) 
to significantly improve the uptake and release of vancomycin (Figure 5b). These composite pellets 
showed no pyrogenic effect, met the clinical requirements on hemolytic reaction and were highly 
biocompatible as demonstrated by early in vitro biological tests. 
 
Figure 5. SEM micrographs of mesoporous silica nano-spheres incorporated in bone cements with a 
matrix of (a) poly(methyl methacrylate) (image adapted from Slane et al. [67] © Elsevier) or (b) 
calcium sulfate needles (image adapted from Li et al. [68] © Elsevier). 
A very interesting application of mesoporous materials in the development of innovative bone 
cements was recently proposed by Tallia et al. [69], who synthesized radiopaque and bioactive 
particles of ZrO2-containing MBG that can be added to injectable materials for minimally invasive 
surgery procedures (e.g., acrylic cement or calcium sulfate), in order to allow the visualization of the 
implant under fluoroscopic control during both injection and follow-up. This research activity, based 
on a patent deposited by Vitale-Brovarone et al. [70], has led to the development of an injectable 
bioresorbable and bioactive cement (Spine-Ghost). Specifically, Spine-Ghost is a composite cement 
formed by a resorbable calcium sulfate matrix enriched by spray-dried MBG particles and a 
radiopaque glass–ceramic phase. Spine-Ghost showed excellent mechanical strength, a very high 
bioactivity, adequate setting times for use in vertebral surgery and radiopacity comparable to the 
commercial reference Cerament® [71]. It was successfully tested on an ad hoc developed sheep 
vertebral model showing suitable cement resorption and excellent bone formation [72]. 
6. Other Types of Composites and Coatings  
Given the high brittleness of sol-gel scaffolds due to their inherent nanoporosity, deposition of 
a silk coating on the struts of MBG foams was rightly thought to improve the mechanical strength of 
the material, although this occurred to a still insufficient extent for safe handling and implantation 
(from 60 to 250 kPa, which is one order of magnitude below the strength of cancellous bone) [73]. 
Another application of polymer-coated MBG foams was reported by Ma et al. [74] who deposited a 
PLGA-magnetic SBA-15 coating on the struts of a cattail-templated MBG scaffold for the dual release 
of ibuprofen and metformin. 
Sol-gel glasses have also found application in soft tissue repair in the form of bioactive coatings 
applied on polymeric sutures for wound dressing. Blaker et al. [75] coated Vycril® and Mersilk® 
resorbable sutures with Ag-doped sol-gel glass powder (60SiO2–34CaO–4P2O5–2Ag2O mol %) by a 
dipping procedure and reported the good in vitro bioactive behavior and bactericidal effect of the 
composite (Figure 6). In another study on the same materials, Pratten et al. [76] compared the 
antimicrobial activity elicited by Mersilk® sutures coated with the same Ag-doped glass with that of 
45S5 Bioglass®-coated sutures against Staphylococcus epidermidis, and reported that Ag-doped samples 
exhibited a significantly greater effect in limiting bacterial attachment. 
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Figure 6. SEM micrographs of a Mersilk® suture coated with Ag-doped sol-gel bioactive glass 
powders (a) before and (b) after soaking for 7 days in SBF (hydroxyapatite agglomerates are clearly 
visible on the suture surface). Images adapted from Blaker et al. [75] © Elsevier.  
7. Beyond Multiphasic Composite Materials: Hybrid Systems  
Over the last decade, there has been much interest to go beyond the classical concept of 
composite and nanocomposite materials, the components of which are distinguishable by a clear 
interface and each of which maintain their peculiar physico-chemical characteristics. The challenge 
has been the development of inorganic–organic hybrid materials in which the components interact 
at the molecular level and are indistinguishable above the nanoscale [77]. This intimate interaction 
should allow cells to come into contact with both phases at one time, and the material should degrade 
at a single rate without having mismatched resorption kinetics of inorganic and organic phases [78]. 
Hybrids are typically synthesized by introducing a polymer in the sol-gel process after 
hydrolysis of the silica precursor alkoxide (e.g., tetraethyl orthosilicate (TEOS)), so that the inorganic 
silica network can form around the polymer molecules and nanoscale interactions between the two 
components can be created. Compared to sol-gel glasses, ageing and drying must be performed to a 
significantly lower temperature (below 100 °C) to avoid degradation of the system. In general, 
bioactive sol-gel hybrids are expected to have bioactivity similar to that of bioactive glasses but 
superior toughness and controlled congruent degradation [79]. This new class of biomaterials has 
been recently reviewed in detail by Jones [80] and Owens et al. [15]. 
Hybrid sol-gel materials can be classified into two classes depending on the interactions between 
the inorganic and organic chains [76]. Class I comprises hybrids that do not contain covalent or ionic-
covalent bonds between the organic and inorganic phases, but each component interacts by only 
weak interactions, such as H-bond, Van der Waals bond, π–π interaction or electrostatic forces. 
Typically, the polymer is “mechanically” entrapped in the silica network during condensation, and 
the inorganic and organic chains are held together by H-bonding to the Si–OH surface groups. 
Biocompatible and degradable polymers of natural and synthetic origin have been used for 
biomedical applications, such as poly(vinyl alcohol) (PVA) [81,82], PCL [83,84], gelatin [85] and 
chitosan [86–88]. 
On the contrary, class-II hybrids include materials in which a part of the organic and inorganic 
components is linked to each other by strong chemical bonds such as covalent or ionic-covalent bonds 
(Figure 7). For this purpose, we can use either a polymer that already contains silane bonds (e.g., 
poly(dimethoxysilane) [89]) or the polymer can be functionalized with a coupling agent before being 
introduced in the sol-gel process (e.g., poly(ethylene glycol) (PEG)-SiO2 class-II hybrids synthesized 
by using triethoxysilyl-terminated PEG and TEOS [90]). 
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Figure 7. Schematic illustration of the interpenetrating inorganic and organic networks of a typical 
class-II hybrid material. Three nanoparticles of the continuous silica network are highlighted. The 
polymer chains are bonded to the silica network by a coupling agent (3-
glycidyloxypropyl)trimethoxysilane (GPTMS)). Carboxylic acid groups on the polymer act as 
nucleophiles to open the epoxy ring of the GPTMS and form a bond. Image adapted from Jones [79] 
© Elsevier. 
The synthesis of an interesting type of hybrids, called “cerasomes”, was recently reported by 
Katagiri et al. [91]; these nanostructures mimic natural liposomes and were produced by a dual 
process of sol-gel and self-assembly of organoalkoxysilanes. Potential applications include the 
modelling of biological membranes to investigate the diffusion of ions and lipophilic substances 
through them [92] as well as the development of new drug delivery systems since cerasomes are able 
to incorporate different organophylic molecules [93]. 
A very special type of class-II hybrids includes the so-called “star gels”, which have an organic 
core surrounded by flexible arms terminated in alkoxysilane groups [94,95] that form a silica-like 
network via hydrolysis and polycondensation. These materials typically hold the excellent bioactivity 
and biocompatibility of sol-gel glasses but exhibit a significantly superior toughness, thereby 
showing promise towards the development of bone-like self-repairing biomaterials [96].  
The development of hybrid biomaterials also has the potential to overcome the issues related to 
the toxicity of (inorganic) nanomaterials. In fact, concerns exist about the fate of nano-sized materials 
in vivo, including the mesoporous silica and bioactive glass nanoparticles released from composite 
materials while the polymeric matrix progressively degrades [97]. At present, a clear consensus in 
the scientific community about this topic does not exist yet and some studies report controversial or 
partial results [98]. Hudson et al. [99] investigated the toxicity of MCM-41 and MCM-48 in rats, and 
reported, on the one hand, a good biocompatibility if the silica particles were injected subcutaneously 
at the sciatic nerve but, on the other hand, a lethal effect after intra-peritoneal or intra-venous 
injection, which suggested the risk of systemic disease associated to submicronic silica. Guidi et al. 
[100] analyzed the biological effect of MCM-41 nanoparticles (250 and 500 nm) in vitro in the presence 
of A549 and RAW264.7 cell types. It was observed that MCM-41 spheres were incorporated within 
endocytic vacuoles and induced DNA strand breaks and chromosomal alterations in both cell lines.  
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In summary, implantation of hybrid materials that can behave as a single phase and, thus, 
undergo congruent dissolution generating ionic products or residues which can be safely 
metabolized by living tissues and organs could eliminate the risk of the suspected genotoxic effect 
related to the size and dosage of silicate nanomaterials. 
8. Conclusions 
The advent of MBGs revolutionized tissue engineering as these biomaterials allow the 
combination of bone bonding and tissue regeneration abilities with the incorporation (and 
subsequent release) of drugs and growth factors inside the mesopores. If the presence of an ordered 
mesoporosity is indeed the strength of MBGs—being responsible for the excellent bioactivity in vitro 
and in vivo and providing the means to incorporate therapeutic biomolecules—on the other hand, it 
also represents the major weakness of these materials, since it implies a certain sacrifice of the 
mechanical properties. This drawback can be mitigated if MBGs are not used alone but are 
incorporated, for example, in a polymeric matrix to produce a composite or are applied as a coating 
on a stronger substrate, such as a glass–ceramic scaffold. However, MBG-containing composites still 
suffer from some limitations, including interfacial weakness between the components, different 
degradation rates between the organic and inorganic phase, and risk of toxicity associated to the 
nano-sized mesoporous products released into the body. The latest research directions are addressed 
to overcoming these problems by the development of inorganic–organic hybrid systems, which 
degrade at a single rate, are tough and hold the high bioactivity of sol-gel glasses. 
9. Methods of Literature Search 
A search of the SCOPUS database was conducted from 2000 to 2016 with a subsequent review 
of accompanying references. Major keywords used singly or in combination included composite, sol-
gel, bioactive glass, mesoporous, hierarchical, silicate, scaffold, coating, cement, tissue engineering, 
and hybrid. Additional references were taken from the bibliography of the references identified 
through the SCOPUS search, and only the most pertinent have been referenced here. 
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